Capucine Baldini

15PUBLICATIONS
137CO-AUTHORS
Cancer diagnosisPredictive and prognostic markersMolecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 27, 2026
Optimizing Portal Venous Phase Acquisition Quality of Contrast-Enhanced CT in Oncology.

|Sep 23, 2026
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.

|Jul 15, 2026
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

|Apr 01, 2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

|Jun 01, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein, Armelle Vinceneux, Debbie Robbrecht

Pageof 3

Frequent Collaborators

4 joint publications

Aurelien Marabelle

3 joint publications

Christophe Massard

3 joint publications

Vincent Goldschmidt

3 joint publications

Stéphane Champiat